From Generics
to Gene Therapy
with AI for Eyecare
From Australia, to the world
From Generics to Gene Therapy with AI for Eyecare
MedicVision AI is pioneering the future of ophthalmic care by addressing the supply gaps in generic eye theraputic needs across Australia, New Zealand and South East Asia, with TGA approved generics for a wide range of opthalmology conditions.
​
Through our groundbreaking partnership with the Centre for Eye Research Australia (CERA), we're developing AI-based diagnostic platforms and revolutionary gene therapies for inherited retinal diseases—starting with Usher Syndrome, the leading cause of hereditary deaf-blindness.
The Convergence of Quality
"Leveraging high-standard ophthalmology generics, to fund and fuel the disruptive potential of AI diagnostics and gene therapy innovation"​​
​While developing tomorrow's breakthrough therapies, we're addressing critical eye care gaps across the Asia-Pacific region , with opthalmology generics that have proven to be effcetive in vision management.
Our Dual Focus​
​
​AI & Gene Therapy Innovation
CERA partnership developing RNA base editing treatments and AI diagnostic platforms​​
​
Accessible Eyecare Today
Quality therapeutic solutions addressing myopia, dry eye, and retinal health across Asia-Pacific
News & Insights
